Cartesian Therapeutics Future Growth
Future criteria checks 0/6
Cartesian Therapeutics is forecast to grow earnings and revenue by 80.3% and 24.3% per annum respectively while EPS is expected to grow by 130.4% per annum.
Key information
80.3%
Earnings growth rate
130.4%
EPS growth rate
| Biotechs earnings growth | 31.5% |
| Revenue growth rate | 24.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 23 Apr 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | N/A | -49 | N/A | 2 |
| 12/31/2025 | N/A | -65 | -39 | -47 | 3 |
| 12/31/2024 | N/A | -38 | -21 | -30 | 3 |
| 12/31/2023 | 26 | -257 | -51 | -51 | N/A |
| 9/30/2023 | 0 | -9 | -8 | -8 | N/A |
| 12/31/2022 | 111 | 35 | -33 | -32 | N/A |
| 12/31/2021 | 85 | -26 | -61 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1S70 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1S70 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1S70 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1S70 is forecast to have no revenue next year.
High Growth Revenue: 1S70 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1S70's Return on Equity is forecast to be high in 3 years time